{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:48Z","timestamp":1772177508515,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Microtransplantation (MST) combines chemotherapy with infusion of HLA-mismatched granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (G-PBSCs) without graft-versus-host disease (GVHD) prophylaxis, offering a potential therapeutic alternative for older acute myeloid leukemia (AML) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center study, 29 patients aged \u226560 years with newly diagnosed non-acute promyelocytic leukemia (AML) received MST between April 2008 and June 2021. Patients were stratified into two age cohorts: 60\u201370 years (\n                      <jats:italic>n<\/jats:italic>\n                      = 20) and &amp;gt;70 years (\n                      <jats:italic>n<\/jats:italic>\n                      = 9). Each MST course comprised induction or consolidation chemotherapy followed by G-PBSC infusion. Donor chimerism was monitored by the InDels assay. Endpoints included complete remission (CR), overall survival (OS), leukemia-free survival (LFS), relapse, non-relapse mortality (NRM), and safety. Competing risk analysis (Fine\u2013Gray model) was used to evaluate the cumulative incidence of relapse and NRM. Transcriptomic profiling was performed in a subset of long-term survivors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up was 148.5 months (range 52.96\u2013219.12). The CR rate was 86.2% (25\/29), with no significant difference between age groups (90.0% vs. 66.7%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.290). The median OS was 20.00 months (range 1.00\u2013205.00). Patients aged 60\u201370 years had significantly better OS than those &amp;gt;70 years (50.0% vs. 10.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002). Similarly, LFS was higher in the younger group (45.0% vs. 10.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015). Receiving &amp;gt;3 MST courses was associated with longer OS and LFS (both\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Competing risk analysis showed a significantly higher cumulative incidence of relapse in the &amp;gt;70-year group (66.7% vs. 45.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.048). NRM did not differ significantly between groups (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.13). GVHD occurred in one patient (3.4%). Transcriptomic analysis of four survivors revealed distinct gene expression profiles enriched in immune and hematopoietic pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MST is an effective and tolerable treatment for older AML patients, particularly those aged 60\u201370 years and those receiving more than three treatment courses. These results support MST as a viable alternative for older patients ineligible for intensive transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1736302","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:10Z","timestamp":1772169910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Microtransplantation improves the outcome of older patients with newly diagnosed acute myeloid leukemia: a single-center study with long-term follow-up"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, People\u2019s Liberation Army (PLA) Rocket Force Characteristic Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-mei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, People\u2019s Liberation Army (PLA) Rocket Force Characteristic Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-shuang","family":"Li","sequence":"additional","affiliation":[{"name":"College of Life Science and Bioengineering, Beijing Jiaotong University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"College of Life Science and Bioengineering, Beijing Jiaotong University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-pan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, People\u2019s Liberation Army (PLA) Rocket Force Characteristic Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-kun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, People\u2019s Liberation Army (PLA) Rocket Force Characteristic Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"College of Life Science and Bioengineering, Beijing Jiaotong University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-jun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, People\u2019s Liberation Army (PLA) Rocket Force Characteristic Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1159\/000486228","article-title":"Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013","volume-title":"Acta Haematol","author":"Song","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.09.005","article-title":"Is the overall survival for older adults with AML finally improving","volume":"31","author":"Lancet","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000486228","article-title":"Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001\u20132013","volume":"139","author":"Song","year":"2018","journal-title":"Acta Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","article-title":"Precision therapy for acute myeloid leukemia","volume":"11","author":"Yang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0449-1","article-title":"Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy","volume":"33","author":"El-Jawahri","year":"2019","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"15","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198093","article-title":"A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2020.03.016","article-title":"Indications and management of hematologic microtransplantation: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)","volume":"107","author":"Cornillon","year":"2020","journal-title":"Bull Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2019.0295","article-title":"Donor selection in HLA-mismatched hematopoietic stem cell microtransplantation for acute myeloid leukemia","volume":"29","author":"Hu","year":"2020","journal-title":"Stem Cells Dev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2017.2656","article-title":"HLA-mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: results from the Microtransplantation Interest Group","volume":"4","author":"Guo","year":"2018","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.01.085","article-title":"Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia","volume":"23","author":"Zhu","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.2995","article-title":"Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia","volume":"9","author":"Kong","year":"2015","journal-title":"Oncol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0281","article-title":"HLA-mismatched stem-cell microtransplantation as post remission therapy for acute myeloid leukemia: long-term follow-up","volume":"30","author":"Guo","year":"2012","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25781","article-title":"Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects","volume":"95","author":"Sung","year":"2020","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1706","article-title":"Microtransplantation for acute myeloid leukemia: A systematic review","volume":"6","author":"Pan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2016-08-733196","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62105-8","article-title":"Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes","volume":"376","author":"Krug","year":"2010","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.858018","article-title":"Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients","volume":"6","author":"Isidori","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/medsci1010037","article-title":"Cellular immunotherapy: using alloreactivity to induce anti-leukemic responses without prolonged persistence of donor cells","volume":"1","author":"Fast","year":"2013","journal-title":"Med Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000470","article-title":"Microtransplantation: clinical applications and mechanisms","volume":"25","author":"Cai","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.08.018","article-title":"The existence and role of microchimerism after microtransplantation","volume":"38","author":"Sun","year":"2014","journal-title":"Leuk Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.08.018","article-title":"Cooperation of CD4+T cells and CD8+ T cells and release of IFN-gamma are critical for antileukemia responses of recipient mice treated by microtransplantation","volume":"15","author":"Wang","year":"2018","journal-title":"Exp Ther Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2040620719882822","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"Richard-Carpentier","year":"2019","journal-title":"Ther Adv Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1736302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:13Z","timestamp":1772169913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1736302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1736302"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1736302","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1736302"}}